GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis
Oncol Res. 2024 Mar 20;32(4):727-736. doi: 10.32604/or.2023.043391. eCollection 2024.ABSTRACTPrimary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable di...
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Guoqiang Hou Xinhang Xu Weixing Hu Source Type: research
IQGAP3 promotes the progression of glioma as an immune and prognostic marker
Conclusion: IQGAP3 shows promise as a valuable biomarker for diagnosis, prognosis, and immunotherapeutic strategies in gliomas.PMID:38560572 | PMC:PMC10972721 | DOI:10.32604/or.2023.046712 (Source: Oncology Research)
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Xiaofeng Gao Juanjuan Ge Xuzheng Gao N A Mei Yanting Su Shigang Shan Wenbin Qian Jiangheng Guan Zhenwang Zhang Long Wang Source Type: research
GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis
Oncol Res. 2024 Mar 20;32(4):727-736. doi: 10.32604/or.2023.043391. eCollection 2024.ABSTRACTPrimary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable di...
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Guoqiang Hou Xinhang Xu Weixing Hu Source Type: research
IQGAP3 promotes the progression of glioma as an immune and prognostic marker
Conclusion: IQGAP3 shows promise as a valuable biomarker for diagnosis, prognosis, and immunotherapeutic strategies in gliomas.PMID:38560572 | PMC:PMC10972721 | DOI:10.32604/or.2023.046712 (Source: Oncology Research)
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Xiaofeng Gao Juanjuan Ge Xuzheng Gao N A Mei Yanting Su Shigang Shan Wenbin Qian Jiangheng Guan Zhenwang Zhang Long Wang Source Type: research
GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis
Oncol Res. 2024 Mar 20;32(4):727-736. doi: 10.32604/or.2023.043391. eCollection 2024.ABSTRACTPrimary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable di...
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Guoqiang Hou Xinhang Xu Weixing Hu Source Type: research
IQGAP3 promotes the progression of glioma as an immune and prognostic marker
Conclusion: IQGAP3 shows promise as a valuable biomarker for diagnosis, prognosis, and immunotherapeutic strategies in gliomas.PMID:38560572 | PMC:PMC10972721 | DOI:10.32604/or.2023.046712 (Source: Oncology Research)
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Xiaofeng Gao Juanjuan Ge Xuzheng Gao N A Mei Yanting Su Shigang Shan Wenbin Qian Jiangheng Guan Zhenwang Zhang Long Wang Source Type: research
GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis
Oncol Res. 2024 Mar 20;32(4):727-736. doi: 10.32604/or.2023.043391. eCollection 2024.ABSTRACTPrimary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable di...
Source: Oncology Research - April 1, 2024 Category: Cancer & Oncology Authors: Guoqiang Hou Xinhang Xu Weixing Hu Source Type: research
EZH2 Promotes Glioma Cell Proliferation, Invasion, and Migration via Mir-142-3p/KCNQ1OT1/HMGB3 Axis
In conclusion, EZH2 curbed miR-142-3p expression, thereby relieving the inhibition of KCNQ1OT1 expression by miR-142-3p, enhancing the binding of KCNQ1OT1 to LIN28B, elevating HMGB3 expression, and ultimately accelerating glioma cell proliferation, invasion, and migration. (Source: Molecular Neurobiology)
Source: Molecular Neurobiology - April 1, 2024 Category: Neurology Source Type: research
Advances in pediatric gliomas: from molecular characterization to personalized treatments
Conclusion: The increasing understanding of the molecular biology characterizing pediatric low and high grade gliomas has revolutionized treatment options for these patients, especially in pLGG. The implementation of next generation sequencing techniques for these tumors is crucial in obtaining less toxic and more efficacious treatments.What is Known:• Pediatric Gliomas are the most common brain tumour in children. They are responsible for significant morbidity and mortality in this population.What is New:• Over the last two decades, there has been a significant increase in our global understanding of the molecular bac...
Source: European Journal of Pediatrics - April 1, 2024 Category: Pediatrics Source Type: research
Tumor suppressor role of the complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas
The complement inhibitor CSMD1 acts as a tumor suppressor in various types of solid cancers. Despite its high level of expression in the brain, its function in gliomas, malignant brain tumors originating from ... (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - April 1, 2024 Category: Cancer & Oncology Authors: Emre Can Tuysuz, Eleni Mourati, Rebecca Rosberg, Aleksandra Moskal, Chrysostomi Gialeli, Elinn Johansson, Valeria Governa, Mattias Belting, Alexander Pietras and Anna M. Blom Tags: Research Source Type: research
Expression of KCNN4 in adult-type diffuse gliomas and its correlations with clinicopathological features and patient prognosis
CONCLUSIONS: KCNN4 was identified to be overexpressed in glioma cells and its expression level is positively related to tumor malignancy. It potentially participates in glioma biology by affecting extracellular regulation, subcellular trafficking, and immune escape. Additionally, high KCNN4 expression was correlated with poor survival outcomes of patients. The results can shed new light on the mechanisms of glioma progression, and provide a potential therapeutic target for treating gliomas.PMID:38555740 | DOI:10.1016/j.tranon.2024.101947 (Source: Translational Oncology)
Source: Translational Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Jun Yang Zhuonan Pu Xiaorong Tao Jiajia Liu Ke Li Jiawei Shi Hui Qiao Xing Fan Source Type: research
Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2
In conclusion, (ACGs + Rh2)-Lipo not only alleviated the toxicity of ACGs to the organism, but also enhanced their anti-tumor activity, which is expected to break through their bottleneck.PMID:38555735 | DOI:10.1080/10717544.2024.2324716 (Source: Drug Delivery)
Source: Drug Delivery - March 31, 2024 Category: Drugs & Pharmacology Authors: Hui Ao Huizhu Song Jing Li Xiangtao Wang Source Type: research
Expression of KCNN4 in adult-type diffuse gliomas and its correlations with clinicopathological features and patient prognosis
CONCLUSIONS: KCNN4 was identified to be overexpressed in glioma cells and its expression level is positively related to tumor malignancy. It potentially participates in glioma biology by affecting extracellular regulation, subcellular trafficking, and immune escape. Additionally, high KCNN4 expression was correlated with poor survival outcomes of patients. The results can shed new light on the mechanisms of glioma progression, and provide a potential therapeutic target for treating gliomas.PMID:38555740 | DOI:10.1016/j.tranon.2024.101947 (Source: Translational Oncology)
Source: Translational Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Jun Yang Zhuonan Pu Xiaorong Tao Jiajia Liu Ke Li Jiawei Shi Hui Qiao Xing Fan Source Type: research
Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2
In conclusion, (ACGs + Rh2)-Lipo not only alleviated the toxicity of ACGs to the organism, but also enhanced their anti-tumor activity, which is expected to break through their bottleneck.PMID:38555735 | PMC:PMC10984232 | DOI:10.1080/10717544.2024.2324716 (Source: Drug Delivery)
Source: Drug Delivery - March 31, 2024 Category: Drugs & Pharmacology Authors: Hui Ao Huizhu Song Jing Li Xiangtao Wang Source Type: research
Expression of KCNN4 in adult-type diffuse gliomas and its correlations with clinicopathological features and patient prognosis
CONCLUSIONS: KCNN4 was identified to be overexpressed in glioma cells and its expression level is positively related to tumor malignancy. It potentially participates in glioma biology by affecting extracellular regulation, subcellular trafficking, and immune escape. Additionally, high KCNN4 expression was correlated with poor survival outcomes of patients. The results can shed new light on the mechanisms of glioma progression, and provide a potential therapeutic target for treating gliomas.PMID:38555740 | DOI:10.1016/j.tranon.2024.101947 (Source: Translational Oncology)
Source: Translational Oncology - March 31, 2024 Category: Cancer & Oncology Authors: Jun Yang Zhuonan Pu Xiaorong Tao Jiajia Liu Ke Li Jiawei Shi Hui Qiao Xing Fan Source Type: research
